Upregulation of miR-26a can ameliorate hypertension-induced cardiac fibrosis through directly inhibiting the expression of fibrosis-related genes, such as Enhancer of Zeste Homolog 2 (EZH2), CTGF, and SMAD4 (15). This evidence concerns the gene EZH2 and Hypertension.